Global Health Limited
Global Health Limited Fundamental Analysis
Global Health Limited (MEDANTA.NS) shows moderate financial fundamentals with a PE ratio of 60.33, profit margin of 12.29%, and ROE of 15.09%. The company generates $41.9B in annual revenue with strong year-over-year growth of 12.74%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 64.5/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze MEDANTA.NS's fundamental strength across five key dimensions:
Efficiency Score
WeakMEDANTA.NS struggles to generate sufficient returns from assets.
Valuation Score
ModerateMEDANTA.NS shows balanced valuation metrics.
Growth Score
ModerateMEDANTA.NS shows steady but slowing expansion.
Financial Health Score
ExcellentMEDANTA.NS maintains a strong and stable balance sheet.
Profitability Score
WeakMEDANTA.NS struggles to sustain strong margins.
Key Financial Metrics
Is MEDANTA.NS Expensive or Cheap?
P/E Ratio
MEDANTA.NS trades at 60.33 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, MEDANTA.NS's PEG of -7.08 indicates potential undervaluation.
Price to Book
The market values Global Health Limited at 8.36 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 32.14 times EBITDA. This signals the market has high growth expectations.
How Well Does MEDANTA.NS Make Money?
Net Profit Margin
For every $100 in sales, Global Health Limited keeps $12.29 as profit after all expenses.
Operating Margin
Core operations generate 21.55 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $15.09 in profit for every $100 of shareholder equity.
ROA
Global Health Limited generates $9.50 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Global Health Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Global Health Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
MEDANTA.NS converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
60.33
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-7.08
vs 25 benchmark
P/B Ratio
Price to book value ratio
8.36
vs 25 benchmark
P/S Ratio
Price to sales ratio
7.42
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.25
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.40
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.15
vs 25 benchmark
ROA
Return on assets percentage
0.09
vs 25 benchmark
ROCE
Return on capital employed
0.19
vs 25 benchmark
How MEDANTA.NS Stacks Against Its Sector Peers
| Metric | MEDANTA.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 60.33 | 29.45 | Worse (Expensive) |
| ROE | 15.09% | 779.00% | Weak |
| Net Margin | 12.29% | -24936.00% (disorted) | Strong |
| Debt/Equity | 0.25 | 0.26 | Neutral |
| Current Ratio | 2.40 | 4.65 | Strong Liquidity |
| ROA | 9.50% | -19344.00% (disorted) | Weak |
MEDANTA.NS outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Global Health Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
132.30%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
1134.50%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
231.89%
Industry Style: Defensive, Growth, Innovation
High Growth